文献速递甲状腺疾病

分子检测预测初诊无侧颈或远处转移的分化型甲状腺癌初始治疗后不完全反应:回顾性队列研究

Molecular Testing Predicts Incomplete Response to Initial Therapy in Differentiated Thyroid Carcinoma Without Lateral Neck or Distant Metastasis at Presentation: Retrospective Cohort Study.
PubMed 文献 · Thyroid · 2023-04-28

该回顾性队列研究纳入945例初诊无侧颈淋巴结转移或远处转移的分化型甲状腺癌患者,评估术前常规因素及分子检测(MT)与初始治疗后不完全反应的关系。中位随访18个月,50例(5.2%)复发。多变量分析仅肿瘤大小与复发相关(OR 1.3,95%CI 1.1-1.5)。在440例有MT结果的患者中,MT结果与复发相关(p < 0.001),纳入MT使c统计量提高27%,与仅纳入ATA风险分层系统的模型无统计学差异(p = 0.15)。

要点

  • 945例患者中50例(5.2%)复发,中位随访18个月。
  • ATA风险分层低、中、高危组复发分别为17例(2.9%)、20例(6.7%)、13例(22.8%)(p < 0.001)。
  • 在440例有MT结果的患者中,肿瘤大小(OR 1.4,95%CI 1.1-1.8)和MT结果(p < 0.001)与复发相关。

核心结论

  • 短期随访中,所有ATA风险分层类别均观察到疾病复发,肿瘤大小是唯一与复发相关的常规术前因素。
  • 纳入MT结果不仅提高了超越肿瘤大小单独预测的能力,而且与金标准ATA风险分层系统能力相似。
  • MT结果可能有助于开发新的术前风险分层算法。

研究设计与样本

  • 回顾性队列研究,纳入2017年11月1日至2021年10月31日期间接受初次甲状腺切除术的连续甲状腺癌患者,术前无侧颈疾病或远处转移。
  • 共945例患者纳入分析,其中440例(46.6%)有可用的MT结果。
  • 构建包含术前变量(MT和/或术后可用的ATA风险分层系统)的 logistic 回归模型预测疾病复发(结构性或生化性),使用c统计量和拟合优度检验比较模型区分度。

主要发现

  • 945例患者中50例(5.2%)复发,中位随访18个月。
  • ATA风险分层低、中、高危组复发分别为17例(2.9%)、20例(6.7%)、13例(22.8%)(p < 0.001)。
  • 多变量分析中,仅肿瘤大小与复发相关(OR 1.3,95%CI 1.1-1.5)。
  • 在440例有MT结果的患者中,复发与较大肿瘤大小(OR 1.4,95%CI 1.1-1.8)和MT结果(p < 0.001)相关。
  • 纳入MT使c统计量提高27%,与仅纳入ATA风险分层系统的模型相比无统计学差异(p = 0.15)。

关键数值与推荐

  • ATA风险分层低危组复发17例(2.9%),中危组20例(6.7%),高危组13例(22.8%)(p < 0.001)。
  • 多变量分析中肿瘤大小与复发的OR为1.3(95%CI 1.1-1.5)。
  • 有MT结果的亚组中,肿瘤大小OR为1.4(95%CI 1.1-1.8),MT结果p < 0.001。
  • 纳入MT使c统计量提高27%,与仅纳入ATA风险分层系统的模型比较p = 0.15。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Molecular testing (MT) is emerging as a potential prognostic factor that can be available before treatment of differentiated thyroid carcinoma begins. Among patients eligible for either lobectomy or total thyroidectomy as their initial therapy, our study aims were to assess (1) if conventionally available preoperative factors are associated with incomplete response to initial therapy, and (2) if MT results can be a surrogate for the ATA Risk Stratification System (RSS) to estimate risk of recurrence. Methods: The data of consecutive thyroid cancer patients without preoperative lateral neck disease or distant metastasis who underwent index thyroidectomy between November 1, 2017 and October 31, 2021 were reviewed. Logistic regression models including preoperative variables such as MT and/or the postoperatively available RSS were constructed to predict disease recurrence, either structural or biochemical. Model discrimination using the c-statistic and goodness-of-fit test were compared. Results: Among 945 patients studied, 50 (5.2%) recurred with 18-month median follow-up. Recurrences were detected in 17 (2.9%), 20 (6.7%), and 13 (22.8%) patients with RSS-low, -intermediate, and -high cancers, respectively (p < 0.001). In multivariable analysis, only tumor size was associated with recurrence (odds ratio [OR] 1.3, 95% confidence interval [CI] 1.1-1.5). In a different model analyzing 440 (46.6%) patients with available MT results, recurrence was associated with both larger tumor size (OR 1.4 [95% CI 1.1-1.8]) and MT results (p < 0.001). Including MT improved the c-statistic by 27%, which was statistically no different than the model incorporating only the RSS (p = 0.15). Conclusions: Disease recurrence was observed across all ATA RSS categories in short-term follow-up, and tumor size was the only conventional preoperative factor associated with recurrence. When MT results were incorporated, they not only improved predictive ability beyond tumor size alone, but also yielded similar ability as the gold standard ATA RSS. Thus, MT results might aid the development of novel preoperative risk stratification algorithms.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Liu JB, Baugh KA, Ramonell KM, et al. Molecular Testing Predicts Incomplete Response to Initial Therapy in Differentiated Thyroid Carcinoma Without Lateral Neck or Distant Metastasis at Presentation: Retrospective Cohort Study. Thyroid. 2023. PMID: 36974361. doi:10.1089/thy.2023.0060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。